Placebo-controlled trial of potassium supplements in black patients with mild essential hypertension
Placebo-controlled trial of potassium supplements in black patients with mild essential hypertension
复制标题
患有轻度原发性高血压的黑人患者补充钾的安慰剂对照试验
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Obel Ao
中科院分区：
文献类型：
--
作者：
Obel Ao
48 名尚未接受治疗的血压轻度升高的黑人患者参加了一项为期 16 周的双盲临床试验，研究口服钾补充剂（每日 64 mmol）与匹配安慰剂（由带涂层的淀粉制成）的功效和耐受性。治疗开始后 4 周内，钾补充剂使平均仰卧位血压和站立位血压显着降低。接受钾补充剂的 24 名患者的尿钾排泄量显着增加（p 小于 0.001）。研究期间血浆钠和钾浓度或尿钠排泄没有发生显着变化。所有患者都完成了试验，没有出现任何明显的不良反应。这些结果与口服钾补充剂可能对轻度高血压患者产生临床显着程度的降血压作用的前提是一致的。
Forty-eight black patients with mildly increased blood pressure (BP) that had not yet been subjected to treatment took part in a double-blind clinical trial of the efficacy and tolerability of oral potassium supplements (64 mmol daily) versus a matching placebo (made of starch with coating) in a 16-week study. Potassium supplements produced a significant decrease in mean supine and standing BP within 4 weeks after treatment inception. Urinary potassium excretion increased significantly in the 24 patients who received potassium supplements (p less than 0.001). No significant changes occurred in plasma sodium and potassium concentrations or in urinary excretion of sodium during the study. All patients completed the trial without experiencing any notable untoward effects. These results are consistent with the premise that oral potassium supplements may exert hypotensive effects of clinically significant degree in patients with mild hypertension.